{"name":"VBI Vaccines Inc.","slug":"vbi-vaccines-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":395960,"revenueGrowth":-96.3,"grossMargin":0,"rdSpend":7074802,"netIncome":-13895737,"cash":8359915,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2015"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"Sci-B-Vac-Lot A","genericName":"Sci-B-Vac-Lot A","slug":"sci-b-vac-lot-a","indication":"Prevention of hepatitis B infection in adults and adolescents","status":"phase_3"},{"name":"Sci-B-Vac-Lot B","genericName":"Sci-B-Vac-Lot B","slug":"sci-b-vac-lot-b","indication":"Prevention of hepatitis B infection","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"VBI-1501 1.0 μg","genericName":"VBI-1501 1.0 μg","slug":"vbi-1501-1-0-g","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"VBI-1501 1.0 μg","genericName":"VBI-1501 1.0 μg","slug":"vbi-1501-1-0-g","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Sci-B-Vac-Lot A","genericName":"Sci-B-Vac-Lot A","slug":"sci-b-vac-lot-a","phase":"phase_3","mechanism":"Sci-B-Vac is a recombinant hepatitis B vaccine designed to provide improved immunogenicity and broader protection against hepatitis B virus variants.","indications":["Prevention of hepatitis B infection in adults and adolescents"],"catalyst":""},{"name":"Sci-B-Vac-Lot B","genericName":"Sci-B-Vac-Lot B","slug":"sci-b-vac-lot-b","phase":"phase_3","mechanism":"Sci-B-Vac-Lot B is a vaccine that stimulates an immune response against the hepatitis B virus.","indications":["Prevention of hepatitis B infection"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMijgJBVV95cUxNdGZfbzJDOXVlM3ViSzdITXdrSkJBS2tMcXYyaTEtNHJKNGNiNW85TS1DQnE5eUxqdDlHWU1jUUxUTGs4dURxLUpxc0E4Nk1SSDd6VDJuVWlxU29LcWN3TE9kNmFFVTF3Y0VQNTVGNXEzU3VxOFdla1J6NFo0Z19LR2Z6UnFmOEJhY1RCeHlyVnBVRjFfbjdpSTNmWEZRMTB2Tk5JWWNBODVuOExQTWpWM2FlN01jSGtzdFc0a3BmQTJJYkx0a0p5bXNjaWhhZExHcDZCRUxVUnNaNGx3YnRwMWp0TFdYazdCZzNGRHZyWl93SGdyeHI0dGY1ekN3ZXpVTldMNmk1bkZpNUhvQ0E?oc=5","date":"2026-04-07","type":"trial","source":"Barchart.com","summary":"Cytomegalovirus Infection Clinical Trial Pipeline Appears Robust With 15+ Key Pharma Companies Actively Working in the Domain | DelveInsight - Barchart.com","headline":"Cytomegalovirus Infection Clinical Trial Pipeline Appears Robust With 15+ Key Pharma Companies Actively Working in the D","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZ0FVX3lxTE1MbmQySFpXdk11RHZPMzdYc09OQ3FkbVdxUVZndnR0czBwX19MbkVobWFFU3NUNjFtb0V0N1BiSFpQVFllNlJhT2J3WWR0bHFra2xPeWNmdUJOdE1vdV9qeE9wenZYYUE?oc=5","date":"2025-12-15","type":"pipeline","source":"Straits Research","summary":"Dengue Vaccine Market Size, Trends & Growth Report by 2034 - Straits Research","headline":"Dengue Vaccine Market Size, Trends & Growth Report by 2034","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxPc2J0dy1aS1VqalctUUVJc0Y2R2tTT1BlbThaWkhJV3BDM3UyU3NRR09CMlpvTzE2QTdqQ25TUGlMZ3B6eEJWUndnZjdNbnJhbXc3U21SbkxTb2VVckJQanlIM2hERC1VMlBRWkFhQkl6M1hiZTRWYVRBcXppbUtwZF83aUhBRHZkTmtMRllfb0xpZjMwV0pCX3hSY1pCTjVTMDJGN1JLcw?oc=5","date":"2025-05-08","type":"pipeline","source":"Pharmaceutical Technology","summary":"VC firm Vivo Capital outlays $740m for biotech investment - Pharmaceutical Technology","headline":"VC firm Vivo Capital outlays $740m for biotech investment","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-01-27","type":"trial","source":"GlobeNewswire","summary":"Glioblastoma Market, an Area With High Trial Failure And - GlobeNewswire","headline":"Glioblastoma Market, an Area With High Trial Failure And","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxQMm1qX1o1c2pPbm11MVJ5RXBDcmNOblRqdWdGS2RpWHVIejBtRXpfOTFvX3dpQ3Y5MDZVU3JoeldCRnRPQThWanRnRGNLSkYtMFI0WXJwdGF3cFB5SGJVRmwwcW1sRklURm9GMDZSOHVveldjUlZFWF84cVhWQmJWbVZGNnlJLWNPU1FUODV1ZWRPRW50ajI3c3d6NEx4LVM2clc0?oc=5","date":"2024-05-15","type":"earnings","source":"VBI Vaccines","summary":"VBI Vaccines Reports First Quarter 2024 Financial Results - VBI Vaccines","headline":"VBI Vaccines Reports First Quarter 2024 Financial Results","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxNbFBpV093WEE3bE1LRF8xaERpVktyNER6QXBhZEktOWF1OXhYb3pjaWo2enJPRmZETTVYRFFvcTZZWXRuUEdXWnVFRXhxSkM3Tl91VGhsT0lwYlBlM3JZV3JvRmg3eFF4ZTVWaGZ0Uk1CdmVLVzgtcWhiaHR5MGhpRkpwcHdTNmZGS2pUekVNMlhwUnM5WXVoTDZESzdnQQ?oc=5","date":"2024-04-16","type":"pipeline","source":"VBI Vaccines","summary":"VBI Vaccines Reports Full Year 2023 Financial Results - VBI Vaccines","headline":"VBI Vaccines Reports Full Year 2023 Financial Results","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxQVllYS1RURGlneVByMTFhMkpMaDBldkl6NGRodjg2Q1NpalJvMkdHUUFCZFFCYlk2QjB2a2hfMngtZTk5d1p0YzR1U015dXE5dnJwSXMzRTh2TEpJSTFZTWxYbDlNcGItUjV1UldXOUJJTF9nTDZKeTZsek5ZWU56QXlNa1d3Q3c4Y3Vueg?oc=5","date":"2022-08-15","type":"pipeline","source":"drugdiscoverytrends.com","summary":"Pharma50: The 22 Most Innovative Biotech Products of 2022 - drugdiscoverytrends.com","headline":"Pharma50: The 22 Most Innovative Biotech Products of 2022","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgJBVV95cUxOUVhQeEwwNDhNMTNsamIyRVBacHRKcXByTE1fZDNrRXB3X1MxUEtLVGNXVWhIR2l0UkpmR19hZGhDTlN3dVhFNmpMTHBwR1NJeWItbWZBY1BCSEZJRUxYU2M5Qmlldk54dE9PZzBXTXVWejNsNGU5aWt0WUR0cWZvbVczTFpjZTlkZGdUVm0xdWVmTXFvbXZ6aHFrcEZkZkV3Z3dFRlUtUEo3cDRZdkNqZmphTVBQODFEelBQN0s5ZWE1SE4tam1NUU1QTGVNRG1ZVldkeDAyaVFyZUtPR0FGUGp2Q25BaWhpTUh6WUUwbG0xdUJjblBpYXcyRzlVRFIwWXJNU19DQlVpdC15eG95OG1n?oc=5","date":"2022-07-26","type":"pipeline","source":"PharmaLive","summary":"The Galien Foundation Announces 2022 Prix Galien USA Nominees in \"Best Biotechnology Product,\" \"Best Pharmaceutical Agent\" and \"Best Medical Technology\" Categories - PharmaLive","headline":"The Galien Foundation Announces 2022 Prix Galien USA Nominees in \"Best Biotechnology Product,\" \"Best Pharmaceutical Agen","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxOMEdWcVdhZUd4RTY2NWR4dWx2VzBNYTNEWmN5VjRUNUFYdHF6RVprV3o5bXh3SFBpWFY3NWhRTFFYeWQwWTJxcHBxbVc5cEZXTW5UeW5nWEVhWmp5QTg5a1JTbEJYdHJKNnYxejgzMFBYeTRZeDZCdG1iRWVTbHB4eHh1WFFBUW12a013STctN0pQclZDTWxMT01IbVFhQ0E?oc=5","date":"2020-08-18","type":"deal","source":"Contract Pharma","summary":"Therapure Signs Manufacturing Deal with VBI Vaccines - Contract Pharma","headline":"Therapure Signs Manufacturing Deal with VBI Vaccines","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxQelg1czg5Q21SU092VFA3aVkxR2s3ZVFrU2Z5U09hUVNlMlFPaDhra3VMWE1mNWp2Zm5UZ29zUF9JM0dIak5fT2lMd0JTMnhfNVZnMll4b2xrc3F3bEFSWE16dERtTWdKd2M2TWlYam9FeXYzV01TOGxIREl5ajJsRU5zX2xJLURqWC10UHd4LUp0V1pxdXZzcTktbG1Sd1R6bl95bjkyOWpJelUzVW5PSThSQW8?oc=5","date":"2018-06-07","type":"trial","source":"Pharmaceutical Technology","summary":"After positive vaccine study, VBI looks to untapped congenital CMV market - Pharmaceutical Technology","headline":"After positive vaccine study, VBI looks to untapped congenital CMV market","sentiment":"positive"},{"date":"2018-05-29","type":"earnings","source":"SEC EDGAR","summary":"SC 13G filed with SEC: SC 13G","headline":"SC 13G Filing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxPT2VHbEJuNGIzS29ReE9QX1FLU0dxYVJ1eGdtRDFrZHZOVlBDbkZWMmdoa1ZTX0xsWk9QYlVLOGYyRkRfNk8wRk9HUW8xaTNDT0tuUzV1dDlWLVdwMGd2SWVxNHBUTlZXS182U2p6VUpJOURnSGY1MEtvd3R4ZHZ3eWJ6T2xGbFpuMUpoUDBCZDNYOXdM?oc=5","date":"2018-05-15","type":"trial","source":"Fierce Pharma","summary":"VBI Vaccines touts positive phase 1 data for CMV vaccine - Fierce Pharma","headline":"VBI Vaccines touts positive phase 1 data for CMV vaccine","sentiment":"positive"},{"date":"2017-03-31","type":"earnings","source":"SEC EDGAR","summary":"SC 13D filed with SEC: SCHEDULE 13D","headline":"SC 13D Filing","sentiment":"neutral"},{"date":"2017-02-10","type":"earnings","source":"SEC EDGAR","summary":"SC 13D filed with SEC: CLARUS LIFESCIENCES I, L.P. VBI VACCINES INC.","headline":"SC 13D Filing","sentiment":"neutral"},{"date":"2016-12-12","type":"earnings","source":"SEC EDGAR","summary":"SC 13D filed with SEC: SC 13D","headline":"SC 13D Filing","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_1":1,"phase_3":2},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":395960,"revenuePeriod":"2015-12-31","revenueHistory":[{"value":395960,"period":"2015-12-31"},{"value":10834123,"period":"2013-12-31"},{"value":10834123,"period":"2013-12-31"},{"value":7724591,"period":"2012-12-31"},{"value":7724591,"period":"2012-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":7074802,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-13895737,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":8359915,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}